Molecular mechanisms of resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
TAN Zhaoli
WANG Youliang
XU Jianming
Abstract：Anti-epidermal growth factor receptor( EGFR) monoclonal antibody is an important therapy for patients with meta-static colorectal cancer( mCRC) . However, due to the presence of intrinsic resistance and the development of acquired resistance, the response rate of anti-EGFR monoclonal antibodies( anti-EGFR mAb) is not satisfied. According to the molecular alteration, this review elaborates with the molecular mechanisms of anti-EGFR mAb in mCRC, providing a reference for further studying on the resistance mechanisms of anti-EGFR mAb and a theoretical basis for individualized therapy in patients with mCRC.
Keywords：Epidermal growth factor receptor( EGFR)Monoclonal antibodyDrug resistanceMutation
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 854-858 )